David A. Siegel Regeneron Pharmaceuticals, Inc. Transaction History
Two Sigma Advisers, LP
- $47 Billion
- Q3 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 926,200 shares of REGN stock, worth $642 Million. This represents 1.11% of its overall portfolio holdings.
Number of Shares
926,200
Previous 938,500
1.31%
Holding current value
$642 Million
Previous $493 Million
5.7%
% of portfolio
1.11%
Previous 1.07%
Shares
28 transactions
Others Institutions Holding REGN
# of Institutions
1,468Shares Held
86.5MCall Options Held
2.38MPut Options Held
1.61M-
Vanguard Group Inc Valley Forge, PA9.05MShares$6.27 Billion0.08% of portfolio
-
Black Rock Inc. New York, NY8.45MShares$5.86 Billion0.2% of portfolio
-
State Street Corp Boston, MA4.69MShares$3.25 Billion0.09% of portfolio
-
Dodge & Cox San Francisco, CA4.55MShares$3.16 Billion1.47% of portfolio
-
Jpmorgan Chase & CO New York, NY4.07MShares$2.82 Billion0.15% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $74.3B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...